Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm primarily due to the presence of the BCR-ABL fusion gene that produces the constitutively active protein, BCR-ABL.
|
31837444 |
2020 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs).
|
31732720 |
2020 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
|
30463063 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
|
30155552 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
In BCR-ABL1-negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia.
|
31340059 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
BCR-ABL1-negative myeloproliferative disorders and chronic myeloid leukaemia are haematologic malignancies characterised by single and mutually exclusive genetic alterations.
|
30965317 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Chronic myeloid leukemia is a myeloproliferative disease where cells of myeloid linage display a t(9;22) chromosomal translocation leading to the formation of the BCR/ABL fusion gene and the continuous activation of tyrosine kinases.
|
31138064 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Inflammatory and oncogenic signaling converge in disease evolution of BCR-ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders characterized by gain-of-function mutation in JAK2 kinase (JAK2V617F), with highest prevalence in patients with polycythemia vera (PV).
|
30967632 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The discovery of somatic mutations within the gene encoding calreticulin (CALR) in 2013 represented a major milestone in the molecular diagnosis of BCR-ABL negative myeloproliferative neoplasms (MPN).
|
28340692 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
This study aimed to elucidate patterns of disease transformation to secondary myelofibrosis (SMF) or secondary acute myeloid leukemia (SAML) and the development of second primary malignancies in South Korean patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs).
|
31765478 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative disorder due to the existence of BCR-ABL fusion protein that allows the cells to keep proliferating uncontrollably.
|
31413564 |
2019 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the constitutive tyrosine kinase (TK) activity of the BCR-ABL1 fusion protein.
|
31122263 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of BCR-ABL fusion gene (GenBank accession NC_000022.11).
|
31206255 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Chronic neutrophilic leukemia (CNL) is a BCR-ABL1-negative myeloproliferative neoplasm with notably dismal survival.
|
30581159 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: The abnormally activated JAK-STAT pathway plays a central role in the pathogenesis of BCR/ABL-negative myeloproliferative neoplasms (MPNs), simultaneously providing a theoretical and clinical basis for the development of small-molecule compounds targeting JAK.
|
31450973 |
2019 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Defining the presence of BCR-ABL transcript in suspected myeloproliferative neoplasm is essential in establishing chronic myeloid leukemia.
|
30772299 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
ABSTRACT: Background The BCR-ABL-negative myeloproliferative neoplasms, i.e., polycythemia vera, essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by mutations in JAK2, CALR, or MPL.
|
30889303 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by JAK-STAT pathway activation, but epigenetic alterations also play an important pathophysiological role.
|
30769020 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Starting from this observation, we extended our study to a panel of human leukemic cells carrying genetic lesions distinctive of different types of leukemias and myeloproliferative disorders (the BCR-ABL1 translocation and the JAK2V617F amino acid substitution) to dissect the cellular events induced by SOX6.
|
30833651 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs).
|
28554272 |
2018 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Thromboembolic events are the main cause of mortality in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) but their underlying mechanisms are largely unrecognized.
|
30103245 |
2018 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
|
28990497 |
2018 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our data, reflecting the largest reported study comprehensively detailing clinicopathologic features and response to therapy, show that the co-occurrence of BCR-ABL1 and JAK2 V617F is rare, with an estimated frequency of 0.4%, and most often reflects two distinct ('composite') myeloproliferative neoplasms.
|
29327708 |
2018 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Genetic factors play a role in the etiology of BCR-ABL-negative myeloproliferative neoplasms (MPNs).
|
30084272 |
2018 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Primary myelofibrosis (PMF) is one of the classic BCR-ABL1 negative myeloproliferative neoplasms (MPN).
|
29256926 |
2018 |